Rogers, G <br/><br/>
Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation.  [electronic resource] 

 -  Health technology assessment (Winchester, England)  2012 
 - 1-410 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review; Systematic Review 
<br/><br/><label>ISSN: </label>2046-4924 
<br/><br/><label>Standard No.: </label>10.3310/hta16220  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Benzamides<br/>Blast Crisis--drug therapy<br/>Clinical Trials as Topic<br/>Cost-Benefit Analysis<br/>Dasatinib<br/>Decision Support Techniques<br/>Disease Progression<br/>Drug Resistance, Neoplasm<br/>Health Care Costs--statistics & numerical data<br/>Humans<br/>Imatinib Mesylate<br/>Incidence<br/>Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy<br/>Leukemia, Myeloid, Accelerated Phase--drug therapy<br/>Leukemia, Myeloid, Chronic-Phase--drug therapy<br/>Models, Economic<br/>Piperazines--pharmacology<br/>Prognosis<br/>Protein Kinase Inhibitors--economics<br/>Pyrimidines--economics<br/>Quality of Life<br/>Thiazoles--economics